5 Top Gainers In Pharma Sector (NTGN, AAC, EKSO...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Neon Therapeutics Inc. (NTGN)

Gained 13.29% to close Thursday's trading at $5.20.

News: No news

The Company's most advanced product candidate is NEO-PV-01, a personal neoantigen vaccine, under phase Ib trials, dubbed NT-001, NT-002, NT-003, and NT-004.

-- NT-001 is exploring the combination of NEO-PV-01 and Bristol Myers' Opdivo in patients with metastatic or advanced melanoma, lung, or bladder cancer. The top-line clinical results, including 12-month follow-up, from this trial, are expected in July 2019. -- NT-002 is testing the combination of NEO-PV-01 and Merck's Keytruda in patients with advanced or metastatic nonsquamous non-small cell lung carcinoma. The immune monitoring and clinical outcome data from this trial are anticipated by the end of Q3 2020. -- NT-003 is evaluating NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab in patients with advanced or metastatic melanoma. Immune monitoring data is expected in the second half of 2020.

2. AAC Holdings Inc. (AAC)

American Addiction Centers is a provider of inpatient and outpatient substance abuse treatment services.

Gained 12.07% to close Thursday's trading at $1.30.

News: No news

Recent event:

On May 9, 2019, the Company reported financial results for the first quarter and year ended March 31, 2019.

Total revenue was $55.4 million in the first quarter of 2019 compared with $81.2 million in the same period in the prior year. Net loss attributable to the stockholders was $22.0 million or $0.90 per share in the recent first quarter compared with net income attributable to stockholders of $1.1 million or $0.04 per share in the prior-year period.

3. Ekso Bionics Holdings Inc. (EKSO)

Ekso is a robotic exoskeleton company offering technologies that help those with paralysis to stand up and walk.

Gained 11.68% to close Thursday's trading at $1.53.

News: The Company has priced its previously announced underwritten public offering of 6.66 million shares of its common stock and accompanying warrants to purchase 6.66 million shares of its common stock at a price to the public of $1.50 per share and accompanying warrant to purchase one share of common stock.

The gross proceeds from the offering are expected to be $10.0 million.

Recent event:

On May 1, 2019, the Company reported financial results for the first quarter ended March 31, 2019.

Net loss applicable to common stockholders for the quarter ended March 31, 2019, narrowed to $6.6 million or $0.10 per share from $7.9 million or $0.13 per share in the year-ago quarter. Revenue was $3.6 million for the quarter ended March 31, 2019, compared to $2.5 million for the quarter ended March 31, 2018.

4. Aerpio Pharmaceuticals Inc. (ARPO)

Aerpio Pharma is a biopharmaceutical company focused on developing treatments for ocular disease.

Gained 8.82% to close Thursday's trading at $1.11.

News: No news

Pipeline & Near-term Catalyst:

The Company's lead product candidate is AKB-9778.

In March of this year, the Company announced that its phase IIb clinical trial of AKB-9778 for patients with moderate to severe non-proliferative diabetic retinopathy, dubbed TIME-2b, did not meet the primary endpoint.

A phase Ib clinical trial to evaluate the safety and pharmacokinetics of a topical drop formulation of AKB-9778 in healthy subjects is expected to be initiated in the second quarter of 2019, with results anticipated by the end of 2019.

5. PAVmed Inc. (PAVM)

PAVmed is a medical device company.

Gained 7.77% to close Thursday's trading at $1.11.

News: No news

Pipeline & Near-term Catalyst:

The lead product candidate is CarpX, a minimally invasive device designed to treat carpal tunnel syndrome.

On May 21, 2019, the first group of nine patients with carpal tunnel syndrome underwent successful CarpX procedures as part of the first-in-human (FIH) clinical safety study being conducted in support of 510(k) re-submission to the FDA. Another group of patients is scheduled to undergo CarpX procedures in the coming weeks.

The Company is planning to resubmit the 510(k) for CarpX once these procedures and their 90-day follow-up are completed.